The suit names manufacturers Eli Lily, Novo Nordisk and Sanofi, and pharmacy benefit management companies CVS Caremark, Express Scripts, and OptumRx.
A lack of competition means both the manufacturing and pharmacy benefits management sector can work together to aggressively increase the cost of the medication. PBMs, the suit said, select insulin products based on rebates they receive from manufacturers, and manufacturers increase prices which results in higher rebates for PBMs.
Wakt until you see what they did with the Covid vaccine. Hold my beer….